GC, 웰빙 품고 헬스케어 키운다…녹십자는 알리글로에 총력

GC Pharma is accelerating its healthcare business by acquiring full control of its wellness subsidiary, generating 505 billion won to fuel the company's global ambitions. The restructuring simplifies decision-making and enables more flexible M&A strategies beyond domestic markets. The financial windfall is expected to be concentrated on establishing Aliglo, the company's groundbreaking blood product, in the US market—a critical milestone after two decades of development.